Industry

Aridhia's Data Platform Used in Major European Research Collaboration to Tackle Alzheimer's Dementia

AridhiaAridhia has announced that it is among 36 organisations behind a ground-breaking Innovative Medicines Initiative research programme that aims to build a platform for efficient testing of innovative treatments for the prevention of Alzheimer's dementia.

Aridhia's data and analytics platform, AnalytiXagility, has been selected for use in the European Prevention of Alzheimer's Dementia (EPAD) project, a powerful research collaboration between European organisations in the public and private sectors which, unlike previous projects, focuses on prevention of dementia in the early stages of the disease.

The project will collaborate with existing cohorts to create a register, identifying 24,000 people across Europe who may be at risk of developing the disease later in life. 6,000 of these people will be invited to join EPAD's cohort of 'at risk' subjects to undergo standardised tests and follow-ups. Of these, approximately 1,500 people will be selected to take part in EPAD's proof of concept adaptive trials of innovative drugs.

Rodrigo Barnes, Chief Technology Officer at Aridhia, said that AnalytiXagility has been chosen because it offers a strong collaborative platform that is accessible to all of the consortium partners and is able to carry out advanced data analytics that can interrogate any kind of data.

"AnalytiXagility offers EPAD a flexible working environment that is collaborative, neutral and has the ability to carry out advanced data analytics during complex trials.

"It will be used as part of a trial engine for the EPAD cohort of 6,000 subjects and the further 1,500 participants who will be asked to take part in the project’s proof of concept adaptive trials of drug candidates or drug combinations that have been specially designed to prevent Alzheimer's dementia.

"With no cure for Alzheimer's and little in the way of treatment, it is vital that we understand and learn how to prevent Alzheimer’s dementia when in its early phases."

The University of Edinburgh is working with Aridhia to trial the EPAD cohort. Professor Craig Ritchie, one of the project’s co-ordinators who is based at the University said: "EPAD is a game-changing project. There is commitment from a wide range of organisations across academia, pharma and public health, to get to the root causes of dementia, to understand how the disease develops over the decades before symptoms become visible, and treat patients at an early stage."

"The EPAD model gives us the opportunity to work together to understand who is more likely the get the disease and how they can be treated early, and effectively."

EPAD promises to deliver a more efficient research model which can streamline the recruitment of patients and enable likely drug candidates to be accelerated straight into Phase III trials, the last stage before a new drug is licenced for use.

Furthermore, all data collected from the cohort will be made public to allow researchers the chance to improve their understanding of the disease, especially in pre-symptomatic phases.

Aridhia's involvement in EPAD cements its commitment to globally significant collaborative research projects, and to addressing one of society’s most challenging diseases. Earlier this year the company announced that AnalytiXagility has been chosen to underpin the three year Moneta Research project, supporting their research into identifying people most likely to develop Alzheimer's dementia.

About Aridhia Informatics
Founded in 2007, Aridhia is a world-leading clinical and translational informatics company developing technology and capability that accelerates the translation of precision medicine and biomedical research into clinical practice. Operating internationally on projects in England, Scotland, Australia, and across Europe, Aridhia works closely with governments, health organisations, research collaborations and academic institutions to transform how care is delivered.

Based in Edinburgh and Glasgow, Aridhia has a 60-strong multidisciplinary team of data scientists, information governance specialists, computer scientists, software developers and healthcare experts.

About the Innovative Medicines Initiative
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA.

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution.

Most Popular Now

Online Therapy Effective at Treatin…

Doctors from the University of Pittsburgh showed that providing an online computerized cognitive behavioral therapy (CCBT) program both alone and in combination with Inte...

Read more

Doctors 2.0 & YOU 2016

26 - 27 May, Paris, France. Doctors 2.0 & YOU, the International Digital Health Congress that offers to every health professionals the opportunity to understand how to u...

Read more

A Personalized Virtual Heart Predic…

When electrical waves in the heart run amok in a condition called arrhythmia, sudden death can occur. To save the life of a patient at risk, doctors currently implant a s...

Read more

Philips Leads Large Scale eHealth I…

Royal Philips (NYSE: PHG; AEX: PHIA) and a consortium of leading European healthcare regions, companies, universities and hospitals today announced the start of the first...

Read more

Ingestible Robot Operates in Simula…

In experiments involving a simulation of the human esophagus and stomach, researchers at MIT, the University of Sheffield, and the Tokyo Institute of Technology have demo...

Read more

Joined-Up Health & Care Confere…

InterSystems, a global leader in health information technology, will bring pioneers from across the world to Sutton Coldfield in May, to share ground-breaking stories on ...

Read more

New Tool Measures Lung Function ove…

Most people in the developing world who have asthma, cystic fibrosis or other chronic lung diseases have no way to measure how well their lungs are functioning outside of...

Read more

Grants4Apps Accelerator 2016: You I…

The Grants4Apps (G4A) Accelerator developed by Bayer invites health IT and technology startups to apply for the program's 2016 edition. This year, Bayer looks primarily i...

Read more

New Photonics Technique to Eliminat…

A team of experts from around Europe has come together to develop a portable device with a hand-held probe that will dramatically reduce invasive diagnostic and therapeut...

Read more

NHS Develops First of its Kind App …

Decades of global stigma over electro-convulsive therapy (ECT), a potentially life-saving treatment that helps thousands of patients with illnesses like severe depression...

Read more

Smartphone App for Monitoring Heart…

A smartphone app that tracks palpitations in heart patients provides comparable performance to the 14-day event monitors that are the current standard of care, according ...

Read more

Philips Telehealth Service for Preg…

Royal Philips (NYSE: PHG, AEX: PHIA) today announced that its Mobile Obstetrics Monitoring (MOM) telehealth service received the highest commendation from the GBCHealth's...

Read more

Digest Newsletter

Subscribe to our weekly Newsletter and stay updated on the latest eHealth News. Subscribe now, it's free!
© eHealthNews.eu 2006 - 2016